These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 2871684)
1. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. del Pozo E; Neufeld M; Schlüter K; Tortosa F; Clarenbach P; Bieder E; Wendel L; Nüesch E; Marbach P; Cramer H Acta Endocrinol (Copenh); 1986 Apr; 111(4):433-9. PubMed ID: 2871684 [TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related]
3. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Spinas GA; Bock A; Keller U Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093 [TBL] [Abstract][Full Text] [Related]
4. Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children. Dickerman Z; Guyda H; Tannenbaum GS J Clin Endocrinol Metab; 1993 Sep; 77(3):652-7. PubMed ID: 8257527 [TBL] [Abstract][Full Text] [Related]
5. Effects of somatostatin analogue SMS 201-995 in normal man. Davies RR; Miller M; Turner SJ; Goodship TH; Cook DB; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG Clin Endocrinol (Oxf); 1986 Jun; 24(6):665-74. PubMed ID: 2878747 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. Williams TC; Kelijman M; Crelin WC; Downs TR; Frohman LA J Clin Endocrinol Metab; 1988 Jan; 66(1):39-45. PubMed ID: 2891721 [TBL] [Abstract][Full Text] [Related]
14. Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. Itoh S; Tanaka K; Kumagae M; Takeda F; Morio K; Kogure M; Hasegawa M; Horiuchi T; Watabe T; Miyabe S Life Sci; 1988; 42(26):2691-9. PubMed ID: 2898717 [TBL] [Abstract][Full Text] [Related]
15. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly. Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093 [TBL] [Abstract][Full Text] [Related]
16. Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. Skamene A; Patel YC Clin Endocrinol (Oxf); 1984 May; 20(5):555-64. PubMed ID: 6146413 [TBL] [Abstract][Full Text] [Related]
18. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas. Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329 [TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). II. Effect on pancreatic and thyroid hormone. Camisa C; Schacht GE; O'Dorisio TM; Maceyko RF Cleve Clin J Med; 1990; 57(1):77-81. PubMed ID: 2407389 [TBL] [Abstract][Full Text] [Related]
20. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. Cordido F; Dieguez C; Casanueva FF J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]